secwatch.observer — SEC 8-K summary
======================================

Issuer:     IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
CIK:        0001425205
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001104659-25-046101
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iovance Q1 2025 revenue $49.3M; FY2025 guidance revised to $250-300M
--------------------------------------------------------------------

- Q1 2025 product revenue $49.3M from Amtagvi ($43.6M) and Proleukin ($5.7M); net loss $116.2M ($0.36 diluted).
- FY2025 total product revenue guidance revised to $250-300M reflecting launch dynamics and ATC growth trajectories.
- Cash and investments $366M as of March 31, 2025; expected to fund operations into second half of 2026.
- Q1 manufacturing capacity reduced by annual maintenance; fully resumed, targeting 100-110 commercial infusions in Q2.
- On track for Amtagvi regulatory approvals in UK, EU, Canada in 2025; NSCLC registrational data in 2H25.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1425205/000110465925046101/0001104659-25-046101-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1425205/000110465925046101/tm2514273d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-046101

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer